◼ Archived
Health
🔮 fades ✓
A breakthrough in pancreatic cancer has experts excited
A new treatment for metastatic pancreatic cancer and KRAS-mutated cancers is generating optimism among experts and patients.
Kras
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Kras
This hub groups 3 separate news trends connected to Kras, spanning July 2, 2026 through July 13, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 18 article observations and 18 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.